Analytical Data
-
Gene name
IMPA2
- Application
-
Alternative Names
IMPA2;IMP.18P;Inositol monophosphatase 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14732
-
Expression Region
1-288aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MKPSGEDQAA LAAGPWEECF QAAVQLALRA GQIIRKALTE EKRVSTKTSA ADLVTETDHL VEDLIISELR ERFPSHRFIA EEAAASGAKC VLTHSPTWII DPIDGTCNFV HRFPTVAVSI GFAVRQELEF GVIYHCTEER LYTGRRGRGA FCNGQRLRVS GETDLSKALV LTEIGPKRDP ATLKLFLSNM ERLLHAKAHG VRVIGSSTLA LCHLASGAAD AYYQFGLHCW DLAAATVIIR EAGGIVIDTS GGPLDLMACR VVAASTREMA MLIAQALQTI NYGRDDEK
-
Molecular Weight
34 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IMPA2, or Inositol Monophosphatase 2, is an enzyme that plays a critical role in inositol phosphate metabolism, which is essential for various cellular signaling pathways. Research into IMPA2 has gained significance due to its involvement in neurological processes and potential links to neurodegenerative diseases, mood disorders, and metabolic syndromes. Unlike its homolog IMPA1, IMPA2 exhibits distinct tissue distribution and regulatory mechanisms, making it a unique target for therapeutic interventions. Studies have shown that altering IMPA2 activity can influence inositol levels, impacting cellular functions such as proliferation, differentiation, and apoptosis. The development of recombinant IMPA2 proteins has enabled researchers to explore the enzyme's biochemical properties, structure-function relationships, and interactions with small molecule inhibitors. Understanding these characteristics is crucial for drug development aimed at modulating IMPA2 activity. Moreover, recombinant IMPA2 can serve as a valuable tool in elucidating the signaling pathways influenced by inositol phosphates, furthering our comprehension of cellular physiology and the molecular basis of associated diseases. As such, IMPA2 represents a promising candidate for targeted therapies, and ongoing research continues to unravel its potential in clinical applications.
